CClinicalTrials.gg
CompletedNCT03379532Updated May 8, 2024

BCI-controlled NMES in Subacute Stroke

An interventional study of BCI-NMES and Sham-NMES in Stroke, sponsored by University Hospital, Geneva. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by University Hospital, Geneva · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Stroke patients with severe upper limb movement deficits have limited treatment options and often remain severely handicapped at the chronic stage.

Recent findings have suggested that poor motor recovery can be due to severe damage of the cortico-spinal tract (CST), the neural fibres connecting the movement regions of the brain to the spinal cord. Hence, to improve recovery of upper limb movements it will be crucial to re-establish and strengthen CST projections.

Recent studies provided evidence that closed-loop brain computer interface-driven electrical stimulation of the paretic muscles can induce clinically important and lasting recovery of upper limb function, even in patients with chronic, severe motor affection. In this treatment approach, movement intentions of the patients are detected with electroencephalography and real-time analyses. This triggers an electrical stimulation of affected upper limb muscles.

In this study, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to voluntary activation of primary motor cortex, as detected by a brain-computer interface (BCI), can help restore CST projections. This might improve recovery of patients with severe upper limb movement deficits. Treatment will be started within the first 8 weeks after stroke onset.

02

Conditions studied

  • Stroke

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Ischemic or hemorrhagic stroke
  • Stroke onset ≤ 8 weeks
  • Severe, unilateral motor upper extremity hemiparesis (≤15 Fugl-Meyer Score)
  • Ability to give informed consent

Exclusion criteria

Exclusion Criteria:

  • Second stroke during rehabilitation
  • Skull breach
  • Cardiac pacemaker
  • Metallic implants in the brain
  • Delirium or disturbed vigilance
  • Inability to follow treatments sessions
  • Severe language comprehension deficits
  • Severe dystonia or spasticity
  • Severe co-morbidity (ex, traumatic, rheumatologic, neurodegenerative diseases)
  • Pregnancy
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Active comparator
    BCI-NMES

    Electrical stimulation of paretic upper limb is triggered contigent to voluntary motor cortex activation of the patient, as detected by the brain-computer interface.

    Device: BCI-NMES

  • Sham comparator
    Sham-NMES

    Electrical stimulation of paretic upper limb is applied independently of motor cortex activation of the patient by using a prerecorded session of another patient.

    Device: Sham-NMES

Interventions

  • DeviceBCI-NMES

    From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.

  • DeviceSham-NMES

    Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.

05

What researchers measure

Primary outcomes

  1. Change in Upper Limb Fugl-Meyer Score, after treatment

    Scale 0-66, higher scores indicate better outcome

    Time frame: Difference between the week before the intervention and the week after intervention

Secondary outcomes

  1. Change in motor evoked potential amplitude of the paretic arm

    Continuous measure, higher amplitude changes indicate better outcome

    Time frame: Difference between the week before the intervention and the week after intervention

  2. Change in fractional anisotropy (FA) of the cortico-spinal tract as determined from diffusion tensor imaging

    FA can have values between 0 and 1, higher values indicate better outcome

    Time frame: Difference between the week before the intervention and the week after intervention

  3. Change in electroencephalography functional connectivity

    Computed from high-density EEG recordings. Continuous measure. Higher values indicate better outcome.

    Time frame: Difference between the week before the intervention and the week after intervention

Other outcomes

  1. Change in Upper Limb Fugl-Meyer Score, follow up

    Scale 0-66, higher scores indicate better outcome

    Time frame: Difference between the week before intervention and 12 weeks after stroke onset

  2. Change in hand grip strength, after intervention

    Jamar dynamometer. Continous measure expressed in kilograms. Higher values indicate better outcome.

    Time frame: Difference between the week before the intervention and the week after intervention

  3. Change in hand grip strength, follow up

    Jamar dynamometer. Continous measure expressed in kilograms. Higher values indicate better outcome.

    Time frame: Difference between the week before intervention and 12 weeks after stroke onset

  4. Change in Functional Independence Measure (FIM) score, after intervention

    Range 18-126, higher values indicate better outcome.

    Time frame: Difference between the week before the intervention and the week after intervention

  5. Change in Functional Independence Measure (FIM) score, follow up

    Range 18-126, higher values indicate better outcome.

    Time frame: Difference between the week before intervention and 12 weeks after stroke onset

  6. Change in Semmes-Weinstein monofilament discrimination test, after intervention

    Range 0.04 to 60 g. Lower values indicate better outcome.

    Time frame: Difference between the week before the intervention and the week after intervention

  7. Change in Semmes-Weinstein monofilament discrimination test, follow up

    Range 0.04 to 60 g. Lower values indicate better outcome.

    Time frame: Difference between the week before intervention and 12 weeks after stroke onset

  8. Change in Modified Ashworth Score, after intervention

    Range 0 to 4. Lower values indicate better outcome.

    Time frame: Difference between the week before the intervention and the week after intervention

  9. Change in Modified Ashworth Score, follow up

    Range 0 to 4. Lower values indicate better outcome.

    Time frame: Difference between the week before intervention and 12 weeks after stroke onset

  10. Change in action research arm test (ARAT) score, after intervention

    Scale range 0-57 points, higher values indicate better outcome.

    Time frame: Difference between the week before the intervention and the week after intervention

  11. Change in action research arm test (ARAT) score, follow up

    Scale range 0-57 points, higher values indicate better outcome.

    Time frame: Difference between the week before intervention and 12 weeks after stroke onset

06

Study locations

2 sites
  • University of Austin
    Austin, Texas 78712, United States
  • Division of Neurorehabilitation, University Hospital of Geneva
    Geneva, GE 1211, Switzerland
07

Registry details

Key details

Study ID
NCT03379532
Lead sponsor
University Hospital, Geneva
Collaborators
Ecole Polytechnique Fédérale de Lausanne, Clinique Romande de Readaptation
Responsible party
Adrian Guggisberg (Médecin adjoint agrégé, assistant professor, University Hospital, Geneva) — Principal investigator
First posted
Dec 20, 2017
Start date
Jan 26, 2018
Primary completion
Mar 31, 2024
Completion
Apr 30, 2024
Last update
May 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion